Combination therapy

What is claimed is: 
     
         1 . A method for treating or preventing cancer comprising administering:
 (i) an effective amount of a compound of Formula (i):   
       
         
           
           
               
               
           
         
         or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein: 
         X, Y, and Z are each independently N or CR X , with the proviso that at least two of X, Y, and Z are nitrogen atoms; where R X  is hydrogen or C 1-6  alkyl; 
         R 1  and R 2  are each independently (a) hydrogen, cyano, halo, or nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R 1a , —C(O)OR 1a , —C(O)NR 1b R 1c , —C(NR 1a )NR 1b R 1c , —OR 1a , —OC(O)R 1a , —OC(O)OR 1a , —OC(O)NR 1b R 1c , —OC(═NR 1a )NR 1b R 1c , —OS(O)R 1a , —OS(O) 2 R 1a , —OS(O)NR 1b R 1c , —OS(O) 2 NR 1b R 1c , —NR 1b R 1c , —NR 1a C(O)R 1d , —NR 1a C(O)OR 1d , —NR 1a C(O)NR 1b R 1c , —NR a C(═NR 1d )NR 1b R 1c , —NR 1a S(O)R 1d , —NR 1a S(O) 2 R 1d , —NR 1a S(O)NR 1b R 1c , —NR 1a S(O) 2 NR 1b R 1c , —SR 1a , —S(O)R 1a , —S(O) 2 R 1a , —S(O)NR 1b R 1c , or —S(O) 2 NR 1b R 1c , wherein each R 1a , R 1b , R 1c , and R 1d  is independently (i) hydrogen; (ii) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (iii) R 1b  and R 1c  together with the N atom to which they are attached form heterocyclyl; 
         R 3  and R 4  are each independently hydrogen or C 1-6  alkyl; or R 3  and R 4  are linked together to form a bond, C 1-6  alkylene, C 2-6  heteroalkylene, C 2-6  alkenylene, or C 2-6  heteroalkenylene; 
         R 5a  is (a) hydrogen or halo; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R 1a , —C(O)OR 1a , —C(O)NR 1b R 1c , —C(NR 1a )NR 1b R 1c , —OR 1a , —OC(O)R 1a , —OC(O)OR 1a , —OC(O)NR 1b R 1c , —OC(═NR 1a )NR 1b R 1c , —OS(O)R 1a , —OS(O) 2 R 1a , —OS(O)NR 1b R 1c , —OS(O) 2 NR 1b R 1c , —NR 1b R 1c , —NR 1a C(O)R 1d , —NR 1a C(O)OR 1d , —NR 1a C(O)NR 1b R 1c , —NR 1a C(═NR 1d )NR 1b R 1c , —NR 1a S(O)R 1d , —NR 1a S(O) 2 R 1d , —NR 1a S(O)NR 1b R 1c , —NR 1a S(O) 2 NR 1b R 1c , —SR 1a , —S(O)R 1a , —S(O) 2 R 1a , —S(O)NR 1b R 1c , or —S(O) 2 NR 1b R 1c ; 
         R 5b  is (a) halo; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R 1a , —C(O)OR 1a , —C(O)NR 1b R 1c , —C(NR 1a )NR 1b R 1c , —OR 1a , —OC(O)R 1a , —OC(O)OR 1a , —OC(O)NR 1b R 1c , —OC(═NR 1a )NR 1b R 1c , —OS(O)R 1a , —OS(O) 2 R 1a ; —OS(O)NR 1b R 1c , —OS(O) 2 NR 1b R 1c , —NR 1b R 1c , —NR 1a C(O)R 1d , —NR 1a C(O)OR 1d , —NR 1a C(O)NR 1b R 1c , —NR 1a C(═NR 1d )NR 1b R 1c , —NR 1a S(O)R 1d , —NR 1a S(O) 2 R 1d , —NR 1a S(O)NR 1b R 1c , —NR 1a S(O) 2 NR 1b R 1c , —SR 1a , —S(O)R 1a , —S(O) 2 R 1a , —S(O)NR 1b R 1c , or —S(O) 2 NR 1b R 1c ; 
         R 5c  is —(CR 5f R 5g ) n —(C 6-14  aryl) or —(CR 5f R 5g )-heteroaryl; 
         R 5d  and R 5e  are each independently (a) hydrogen or halo; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R 1a , —C(O)OR 1a , —C(O)NR 1b R 1c , —C(NR 1a )NR 1b R 1c , —OR 1a , —OC(O)R 1a , —OC(O)OR 1a , —OC(O)NR 1b R 1c , —OC(═NR 1a )NR 1b R 1c , —OS(O)R 1a , —OS(O) 2 R 1a , —OS(O)NR 1b R 1c , —OS(O) 2 NR 1b R 1c , —NR 1b R 1c , —NR 1a C(O)R 1d , —NR 1a C(O)OR 1d , —NR 1a C(O)NR 1b R 1c , —NR 1a C(═NR 1d )NR 1b R 1c , —NR 1a S(O)R 1d , —NR 1a S(O) 2 R 1d , —NR 1a S(O)NR 1b R 1c , —NR 1a S(O) 2 NR 1b R 1c , —SR 1a , —S(O)R 1a , —S(O) 2 R 1a , —S(O)NR 1b R 1c , or —S(O)NR 1b R 1c ; 
         R 5f  and R 5g  are each independently (a) hydrogen or halo; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R 1a , —C(O)OR 1a , —C(O)NR 1b R 1c , —C(NR 1a )NR 1b R 1c , —OR 1a , —OC(O)R 1a , —OC(O)OR 1a , —OC(O)NR 1b R 1c , —OC(═NR 1a )NR 1b R 1c , —OS(O)R 1d , —OS(O) 2 R 1a , —OS(O)NR 1b R 1c , —OS(O) 2 NR 1b R 1c , —NR 1b R 1c , —NR 1a C(O)R 1d , —NR 1a C(O)OR 1d , —NR 1a C(O)NR 1b R 1c , —NR 1a C(═NR 1d )NR 1b R 1c , —NR 1a S(O)R 1d , —NR 1a S(O) 2 R 1d , —NR 1a S(O)NR 1b R 1c , —NR a S(O) 2 NR 1b R 1c , —SR 1a , —S(O)R 1a , —S(O) 2 R 1a , —S(O)NR 1b R 1c ; or —S(O) 2 NR 1b R 1c ; or (d) when one occurrence of R 5f  and one occurrence of R 5g  are attached to the same carbon atom, the R 5f  and R 5g  together with the carbon atom to which they are attached form a C 3-10  cycloalkyl or heterocyclyl; 
         R 6  is hydrogen, C 1-6  alkyl, —S—C 1-6  alkyl, —S(O)—C 1-6  alkyl, or —SO 2 —C 1-6  alkyl; 
         m is 0 or 1; and 
         n is 0, 1, 2, 3, or 4; 
         wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl in R 1 , R 2 , R 3 , R 4 , R 6 , R X , R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , and R 5g  is optionally substituted with one, two, three, four, or five substituents Q, wherein each substituent Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one, two, three, or four, substituents Q a ; and (c) —C(O)R a , —C(O)OR a , —C(O)NR b R c , —C(NR a )NR b R c , —OR a , —OC(O)R a , —OC(O)OR a , —OC(O)NR b R c , —OC(═NR a )NR b R c , —OS(O)R a , —OS(O) 2 R a , —OS(O)NR b R c , —OS(O) 2 NR b R c , —NR b R c , —NR a C(O)R d , —NR a C(O)OR d , —NR a C(O)NR b R c , —NR a C(═NR d )NR b R c , —NR a S(O)R d , —NR a S(O) 2 R d , —NR a S(O)NR b R c , —NR a S(O) 2 NR b R c , —SR a , —S(O)R a , —S(O) 2 R a , —S(O)NR b R c , and —S(O) 2 NR b R c , wherein each R a , R b , R c , and R d  is independently (i) hydrogen; (ii) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl, each of which is further optionally substituted with one, two, three, or four, substituents Q a ; or (iii) R b  and R c  together with the N atom to which they are attached form heterocyclyl, which is further optionally substituted with one, two, three, or four, substituents Q a ; 
         wherein each Q a  is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, and heterocyclyl; and (c) —C(O)R e , —C(O)OR e , —C(O)NR f R g , —C(NR e )NR f R g , —OR e , —OC(O)R e , —OC(O)OR e , —OC(O)NR f R g , —OC(═NR e )NR f R g , —OS(O)R e , —OS(O) 2 R e , —OS(O)NR f R g , —OS(O) 2 NR f R g , —NR f R g , —NR e C(O)R h , —NR e C(O)OR h , —NR e C(O)NR f R g , —NR e C(═NR h )NR f R g , —NR e S(O)R h , —NR e S(O) 2 R h , —NR e S(O)NR f R g , —NR e S(O) 2 NR f R g , —SR e , —S(O)R e , —S(O) 2 R e , —S(O)NR f R g , and —S(O) 2 NR f R g ; wherein each R e , R f , R g , and R h  is independently (i) hydrogen; (ii) C 1-6  alkyl, C 2-6  alkenyl, C 2-6 alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (iii) R f  and R g  together with the N atom to which they are attached form heterocyclyl; 
         wherein two substituents Q that are adjacent to each other optionally form a C 3-10  cycloalkenyl, C 6-14  aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Q a ; 
         and 
         (ii) an effective amount of a CD20 inhibitor. 
       
     
     
         2 . The method of  claim 1 , wherein R 5b  is (a) halo; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, or heteroaryl; or (c) —C(O)R 1a , —C(O)OR 1a , —C(O)NR 1b R 1c , —C(NR 1a )NR 1b R 1c , —OR 1a —, —OC(O)R 1a , —OC(O)OR 1a , —OC(O)NR 1b R 1c , —OC(═NR 1a )NR 1b R 1c , —OS(O)R 1a , —OS(O) 2 R 1a , —OS(O)NR 1b R 1c , —S(O)NR 1b R 1c , —NR 1b R 1c , —NR 1a C(O)R 1d , —NR 1a C(O)OR 1d , —NR 1a C(O)NR 1b R 1c , —NR 1a C(═NR 1d )NR 1b R 1c , —NR 1a S(O)R 1d , —NR 1a S(O) 2 R 1d , —NR 1a S(O)NR 1b R 1c , —NR 1a S(O) 2 NR 1b R 1c , —SR 1a , —S(O)R 1a , —S(O) 2 R 1a , —S(O)NR 1b R 1c , or —S(O) 2 NR 1b R 1c . 
     
     
         3 . The method of  claim 1 , wherein R 5a  and R 5b  are each independently (a) halo; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R 1a , —C(O)OR 1a , —C(O)NR 1b R 1c , —C(NR 1a )NR 1b R 1c , —OR 1a , —OC(O)R 1a , —OC(O)OR 1a , —OC(O)NR 1b R 1c , —OC(═NR 1a )NR 1b R 1c , —OS(O)R 1a , —OS(O) 2 R 1a , —OS(O)NR 1b R 1c , —OS(O) 2 NR 1b R 1c , —NR 1b R 1c , —NR 1a C(O)R 1d , —NR 1a C(O)OR 1d , —NR 1a C(O)NR 1b R 1a , —NR 1a C(═NR 1d )NR 1b R 1c , —NR 1a S(O)R 1d , —NR 1a S(O) 2 R 1d , —NR 1a S(O)NR 1b R 1c , —NR 1a S(O) 2 NR 1b R 1c , —SR 1a , —S(O)R 1a , —S(O) 2 R 1a , —S(O)NR 1b R 1c , or —S(O) 2 NR 1b R 1c . 
     
     
         4 . The method of  claim 3 , wherein R 5a  and R 5b  are each methyl, optionally substituted with one, two, or three halos. 
     
     
         5 . The method of any one of  claims 1 - 4 , wherein n is 1. 
     
     
         6 . The method of any one of  claims 1 - 5 , wherein R 5f  and R 5g  are each hydrogen. 
     
     
         7 . The method of any one of  claims 1 - 4 , wherein n is 0. 
     
     
         8 . The method of any one of  claims 1 - 7 , wherein m is 0. 
     
     
         9 . The method of any one of  claims 1 - 8 , wherein the compound of Formula (I) is of Formula (XI): 
       
         
           
           
               
               
           
         
         or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein: 
         R 7a , R 7b , R 7c , R 7d , and R 7e  are each independently (a) hydrogen, cyano, halo, or nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one, two, three, or four substituents Q a ; or (c) —C(O)R a , —C(O)OR a , —C(O)NR b R c , —C(NR a )NR b R c , —OR a , —OC(O)R a , —OC(O)OR a , —OC(O)NR b R c , —OC(═NR a )NR b R c , —OS(O)R a , —OS(O)R a , —OS(O)NR b R c , —OS(O) 2 NR b R c , —NR b R c , —NR a C(O)R d , —NR a C(O)OR d , —NR a C(O)NR b R c , —NR a C(═NR d )NR b R c , —NR a S(O)R d , —NR c S(O) 2 R d , —NR a S(O)NR b R c , —NR a S(O) 2 NR b R c , —SR a , —S(O)R a , —S(O) 2 R a , —S(O)NR b R c , or —S(O) 2 NR b R c ; or 
         two of R 7a , R 7b , R 7c , R 7d , and R 7e  that are adjacent to each other form C 3-10  cycloalkenyl, C 6-14  aryl, heteroaryl, or heterocyclyl, each optionally substituted with one, two, three, or four substituents Q a . 
       
     
     
         10 . The method of any one of  claims 1 - 9 , wherein the compound of Formula (I) is Compound A35: 
       
         
           
           
               
               
           
         
       
       an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. 
     
     
         11 . The method of any one of  claims 1 - 9 , wherein the compound of Formula (I) is Compound A36: 
       
         
           
           
               
               
           
         
       
       an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. 
     
     
         12 . The method of any one of  claims 1 - 9 , wherein the compound of Formula (I) is Compound A68: 
       
         
           
           
               
               
           
         
       
       an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. 
     
     
         13 . The method of any one of  claims 1 - 9 , wherein the compound of Formula (I) is Compound A70: 
       
         
           
           
               
               
           
         
       
       an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. 
     
     
         14 . The method of any one of  claims 1 - 9 , wherein the compound of Formula (I) is Compound A37: 
       
         
           
           
               
               
           
         
       
       an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. 
     
     
         15 . The method of any one of  claims 1 - 9 , wherein the compound of Formula (I) is Compound A38: 
       
         
           
           
               
               
           
         
       
       an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. 
     
     
         16 . The method of any one of  claims 1 - 9 , wherein the compound of Formula (I) is Compound A41: 
       
         
           
           
               
               
           
         
       
       an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. 
     
     
         17 . The method of any one of  claims 1 - 9 , wherein the compound of Formula (I) is Compound A42: 
       
         
           
           
               
               
           
         
       
       an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. 
     
     
         18 . The method of any one of  claims 1 - 9 , wherein the compound of Formula (I) is Compound A43: 
       
         
           
           
               
               
           
         
       
       an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. 
     
     
         19 . The method of any one of  claims 1 - 9 , wherein the compound of Formula (I) is Compound A44: 
       
         
           
           
               
               
           
         
       
       an isotopic variant thereof, a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. 
     
     
         20 . The method of any one of  claims 1 - 19 , wherein the CD20 inhibitor is ofatumumab, obinutuzumab, rituximab, ocaratuzumab, ocrelizumab, tositumomab, ibritumomab tiuxetan, tisotumab vedotin, ublituximab, TRU-015, veltuzumab, BTCT4465A (RG7828), EDC9, MT-3724, or a variant or biosimilar thereof, or combinations thereof. 
     
     
         21 . The method of  claim 20 , wherein the CD20 inhibitor is ofatumumab or a variant or biosimilar thereof. 
     
     
         22 . The method of  claim 20 , wherein the CD20 inhibitor is obinutuzumab or a variant or biosimilar thereof. 
     
     
         23 . The method of  claim 20 , wherein the CD20 inhibitor is rituximab or a variant or biosimilar thereof. 
     
     
         24 . The method of  claim 20 , wherein the CD20 inhibitor is ocaratuzumab or a variant or biosimilar thereof. 
     
     
         25 . The method of  claim 20 , wherein the CD20 inhibitor is ocrelizumab or a variant or biosimilar thereof. 
     
     
         26 . The method of  claim 20 , wherein the CD20 inhibitor is tositumomab or a variant or biosimilar thereof. 
     
     
         27 . The method of  claim 20 , wherein the CD20 inhibitor is ibritumomab tiuxetan or a variant or biosimilar thereof. 
     
     
         28 . The method of  claim 20 , wherein the CD20 inhibitor is tisotumab vedotin or a variant or biosimilar thereof. 
     
     
         29 . The method of  claim 20 , wherein the CD20 inhibitor is ublituximab or a variant or biosimilar thereof. 
     
     
         30 . The method of  claim 20 , wherein the CD20 inhibitor is TRU-015 or a variant or biosimilar thereof. 
     
     
         31 . The method of  claim 20 , wherein the CD20 inhibitor is veltuzumab or a variant or biosimilar thereof. 
     
     
         32 . The method of  claim 20 , wherein the CD20 inhibitor is BTCT4465A (RG7828) or a variant or biosimilar thereof. 
     
     
         33 . The method of  claim 20 , wherein the CD20 inhibitor is EDC9 or a variant or biosimilar thereof. 
     
     
         34 . The method of  claim 20 , wherein the CD20 inhibitor is MT-3724 or a variant or biosimilar thereof. 
     
     
         35 . The method of any one of  claims 1 - 34 , wherein the cancer is a hematological malignancy. 
     
     
         36 . The method of  claim 35 , wherein the hematological malignancy is a B-cell malignancy. 
     
     
         37 . The method of  claim 36 , wherein the B-cell malignancy is selected from follicular lymphoma, large B cell lymphoma, and chronic lymphocytic leukemia (CLL). 
     
     
         38 . The method of  claim 36 , wherein the B-cell malignancy is selected from chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), marginal zone B cell lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), and high grade non-Hodgkin's lymphoma. 
     
     
         39 . The method of  claim 36 , wherein the B-cell malignancy is selected from chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), marginal zone B cell lymphoma (MZL), or diffuse large B-cell lymphoma (DLBCL). 
     
     
         40 . The method of any one of  claims 1 - 34 , wherein the cancer is relapsed B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL). 
     
     
         41 . The method of any one of  claims 1 - 40 , wherein the administration of compounds occurs in one or more cycles. 
     
     
         42 . The method of any of  claims 1 - 41 , wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and the CD20 inhibitor are administered simultaneously. 
     
     
         43 . The method of any of  claim 1 - 41 , wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and the CD20 inhibitor are administered sequentially. 
     
     
         44 . The method of any of  claims 1 - 43 , wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered orally and the CD20 inhibitor is administered by injection. 
     
     
         45 . The method of any of  claims 1 - 44 , wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered orally and the CD20 inhibitor is administered by intravenous infusion. 
     
     
         46 . The method of any of  claims 1 - 44 , wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered orally and the CD20 inhibitor is administered by subcutaneous injection. 
     
     
         47 . The method of any of  claims 1 - 46 , wherein about 60 mg, about 120 mg, about 150 mg, or about 180 mg of a compound of Formula (I) or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to the subject. 
     
     
         48 . The method of  claim 47 , wherein about 60 mg of a compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to the subject. 
     
     
         49 . The method of  claim 47  or  48 , wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to the subject daily. 
     
     
         50 . The method of any one of  claims 47 - 49 , wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered to the subject once per day, twice per day, or three times per day. 
     
     
         51 . The method of any one  claims 47 - 50 , wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered to the subject once per day. 
     
     
         52 . The method of any one of  claims 47 - 51 , wherein about 60 mg/day of the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof is administered to the subject. 
     
     
         53 . The method of any one of the preceding claims, wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered to the subject on a 28-day cycle. 
     
     
         54 . The method of any one of the preceding claims, wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered to the subject for at least one 28-day cycle. 
     
     
         55 . The method of any one of the preceding claims, wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered to the subject for at least two 28-day cycles. 
     
     
         56 . The method of any one of the preceding claims, wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered to the subject for a period of up to about 7 days. 
     
     
         57 . The method of  claim 56 , wherein the days over which the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof are intermittent. 
     
     
         58 . The method of any one of  claims 1 - 57 , comprising administering to subject the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof for about 7 consecutive days in a 28-day cycle. 
     
     
         59 . The method any one of  claims 1 - 58 , wherein the method comprises an intermittent dosing schedule (IS), comprising administering to subject the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof once daily for 7 consecutive days followed by 21 days without treatment in a 28-day cycle. 
     
     
         60 . The method of  claim 59 , wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered to the subject for at least one 28-day cycle. 
     
     
         61 . The method of any one of  claims 1 - 58 , wherein the method comprises a continuous daily dosing schedule (CS), comprising administering to subject the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof once daily for 28 consecutive days in a 28-day cycle. 
     
     
         62 . The method of  claim 61 , wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is administered to the subject for at least two CS 28-day cycles. 
     
     
         63 . The method of  claim 62 , further comprising an IS, comprising administering to subject the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof once daily for 7 consecutive days followed by 21 days without treatment in a 28-day cycle after the at least two CS 28-day cycles. 
     
     
         64 . The method of any one of the preceding claims, wherein the compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is formulated as a tablet or capsule. 
     
     
         65 . The method of  claim 23 , wherein the rituximab is administered at a dose of about 375 mg/m 2 . 
     
     
         66 . The method of  claim 23  or  65 , wherein 8 doses of rituximab are administered to the subject over a period of about 6 months 
     
     
         67 . The method of any one of the preceding claims, wherein the subject is treated for a period of about 6 months.